Exelixis reports Cabometyx trial results for neuroendocrine tumors

May 30, 2026 10:00 AM

Exelixis Inc. (NASDAQ: EXEL) reported subgroup analysis results from its phase 3 CABINET trial showing that Cabometyx reduced the risk ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found